Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.36 |
| ▸ | SNCA | P37840 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL50237 | 0.82 | PARP1 (0.50) | RAB9AALDH1A1SMN1; SMN2GAAHSD17B10 | |
| SCHEMBL1173615 | 0.81 | KIF11 (0.51) | RAB9AALDH1A1SMN1; SMN2GAAHSD17B10 | |
| SCHEMBL54140 | 0.79 | GABRA1 (0.43) | MAPTNPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL50743 | 0.79 | PARP1 (0.46) | MAPTRAB9AALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL13965805 | 0.78 | CCNA2 (0.36) | MAPTRAB9AALDH1A1SMN1; SMN2GAA | |
| SCHEMBL13286195 | 0.78 | KIF11 (0.41) | MAPTNPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL18661421 | 0.78 | CHEK2 (0.42) | MAPKAPK2MAPTRAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL14435397 | 0.78 | CCNA2 (0.38) | MAPTRAB9AALDH1A1SMN1; SMN2GAA | |
| SCHEMBL5283403 | 0.75 | PARP1 (0.44) | RAB9AALDH1A1SMN1; SMN2NPSR1PARP1 | |
| SCHEMBL27711877 | 0.74 | KDM4E (0.44) | MAPTALDH1A1GAAHSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431568-B2 | Aromatic heterocyclic fused indolobenzadiazepine HCV NS5B inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-30 | — | — | US | disclosed |
| EP-2280978-B1 | PYRROLIDINE FUSED INDOLOBENZADIAZEPINE HCV NS5B INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2013-04-24 | — | — | EP | disclosed |
| US-8119628-B2 | Pyrrolidine fused indolobenzadiazepine HCV NS5B inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-21 | — | — | US | disclosed |
| EP-2278977-B1 | AROMATIC HETEROCYCLIC FUSED INDOLOBENZADIAZEPINE HCV NS5B INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-11-02 | — | — | EP | disclosed |
| EP-2280978-A1 | PYRROLIDINE FUSED INDOLOBENZADIAZEPINE HCV NS5B INHIBITORS | Bristol-Myers Squibb Company (US) | 2011-02-09 | — | — | EP | disclosed |
| EP-2278977-A1 | AROMATIC HETEROCYCLIC FUSED INDOLOBENZADIAZEPINE HCV NS5B INHIBITORS | Bristol-Myers Squibb Company (US) | 2011-02-02 | — | — | EP | disclosed |
| US-20110020276-A1 | Pyrrolidine Fused Indolobenzadiazepine HCV NS5B Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-27 | — | — | US | disclosed |
| US-20110014154-A1 | Aromatic Heterocyclic Fused Indolobenzadiazepine HCV NS5B Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-20 | — | — | US | disclosed |
| WO-2009120650-A1 | AROMATIC HETEROCYCLIC FUSED INDOLOBENZADIAZEPINE HCV NS5B INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-01 | — | — | WO | disclosed |
| WO-2009120733-A1 | PYRROLIDINE FUSED INDOLOBENZADIAZEPINE HCV NS5B INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110014154-A1 | Aromatic Heterocyclic Fused Indolobenzadiazepine HCV NS5B Inhibitors | HAVCR2, NSD2, ZC3HAV1 | MAPKAPK2 3383/4885SNCA 1998/4885MAPT 3277/4885 |
| US-20110020276-A1 | Pyrrolidine Fused Indolobenzadiazepine HCV NS5B Inhibitors | NSD2, EIF2AK2, ZC3HAV1 | MAPKAPK2 2534/4885SNCA 1379/4885MAPT 3461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.